Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05530343 · ClinicalTrials.gov registry record · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
A NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 2,298
- Enrollment target
- 14
- Study locations
NCT05530343 is a NA study of Esophageal Adenocarcinoma and Barrett Esophagus that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 2,298 participants, above the 255-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (801% higher). The trial reports 14 study locations across 11 states.
The verdict
NCT05530343, a NA study of Esophageal Adenocarcinoma and Barrett Esophagus, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,298 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that is used to spot patients at increased risk of developing a type of cancer in the esophagus (swallowing tube) called esophageal adenocarcinoma. The 5-year survival rate is as low as 18% for patients who get esophageal adenocarcinoma, but the rate may be improved if the cancer is caught in its early stages. Barrett's esophagus can lead to dysplasia, or precancerous changes, which occurs when cells look abnormal but have not developed into cancer. If the abnormal cells increase from being slightly abnormal (low-grade dysplasia), to being very abnormal (high-grade dysplasia), the risk of developing cancer (esophageal adenocarcinoma) goes up. Therefore, catching dysplasia early is very important to prevent cancer. Endoscopic surveillance is a type of procedure where endoscopists run a tube with a light and a camera on the end of it down a patients throat and remove a small piece of tissue. The piece of tissue, called a biopsy, is about the size of the tip of a ball-point pen and is checked for abnormal cells and cancer cells. Patients are being asked to be in this research study because they have been diagnosed with BE or suspected to have BE, and will need an esophagogastroduodenoscopy (EGD). Patients with BE undergo sampling using the Seattle biopsy protocol during which samples are obtained from the BE in a four quadrant fashion every 2 cm along with target biopsies from any abnormal areas within the BE. Another sampling approach is WATS3D which utilizes brushings from the BE. While both of these procedures are widely accepted approaches to sampling patients with BE during endoscopy, there is not enough research to show if one is better than the other. Participants in
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Seattle protocol
- DIAGNOSTIC_TEST WATS3D brushings
Study Locations (14)
New York
- Long Island Jewish Medical Center - New Hyde Park
- Weill Cornell Medicine - New York
- University of Rochester - Rochester
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente - Oakland
Arizona
- Arizona Centers of Digestive Health - Gilbert
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- Connecticut Clinical Research Institute - Bristol
Florida
- Suncoast Endoscopy of Sarasota - Sarasota
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,298 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05530343
The ClinicalTrials.gov registry entry for NCT05530343 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,298 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (801% higher). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Seattle protocol is the first listed.
NCT05530343 reports 14 study locations spanning 11 distinct geographic areas - top geographies include New York, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05530343 about?
NCT05530343 is a clinical study titled "Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance". The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that ...
What is the current status of trial NCT05530343?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,298 participants. The study started on 2022-10-03. Estimated completion is 2026-03.
What conditions does trial NCT05530343 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Barretts Esophagus With Dysplasia.
What interventions are being tested in trial NCT05530343?
The interventions under investigation include: Seattle protocol (DIAGNOSTIC_TEST), WATS3D brushings (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05530343?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05530343 being conducted?
This trial has 14 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.